SYNACT Aktie

 

The United States Patent and Trademark Office has issued a Notice of Allowance for SynAct Pharma's patent application covering the use of resomelagon in combination with methotrexate (MTX) for the treatment of rheumatoid arthritis. This indicates that the patent office intends to grant the patent, further strengthening the company's patent portfolio. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/04/synact-pharma-secures-patent-for-resomelagon-in-combination-with-mtx/ This is a press release from BioStock - Connecting Innovation &...

An investigator-initiated phase II study has been launched with SynAct Pharma's lead candidate, resomelagon, in patients with dengue in Brazil. This trial runs in parallel with the ongoing study in rheumatoid arthritis. BioStock spoke with the company's CSO, Thomas Jonassen, who sees strong potential for resomelagon in both RA and dengue, as well as other indications: – We work behind the scenes to expand our pipeline and look forward to presenting the next program(s) once we are ready, says Jonassen. Read the full article at biostock.se (https://www.biostock.se/en/): https://www....

SynAct Pharma has been granted a pivotal US patent protecting the crystal form of resomelagon, a drug candidate currently in phase IIb clinical development for rheumatoid arthritis. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/03/synact-pharma-secures-key-us-patent/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se...

In December, SynAct Pharma successfully completed directed issues raising 45 million SEK and now the rights issue linked to this transaction, raising approximately SEK 20 million, has been completed as well through an oversubscribed transaction conducted at a premium. The subscription rate was 161.8 per cent, thereby eliminating the need to activate guarantee commitments, underscoring strong shareholder support. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2025/01/synact-pharma-announces-oversubscribed-share-issue/ This is a press...

Das Instrument 8F8 SE0008241491 SYNACT PHARMA AB EQUITY wird ex Kapitalmassnahme gehandelt am 16.12.2024 The instrument 8F8 SE0008241491 SYNACT PHARMA AB EQUITY is traded ex capital adjustment on 16.12.2024...

SynAct Pharma has announced a capital raise of approximately SEK 65 million. The funding, subject to approval by an extraordinary general meeting, will be achieved through a combination of directed issues and a fully guaranteed rights issue. This initiative is supported by some of the company's larger shareholders and will fund the continued development of resomelagon in rheumatoid arthritis, for which the company just received EU trial approval for its phase IIb ADVANCE study. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2024/11/new-and-...

SynAct Pharma's Capital Markets Day provided detailed information regarding the revised strategy for its lead asset, resomelagon. The company focuses on the phase IIb ADVANCE study in early, severe rheumatoid arthritis, which is now up and running in the US. In parallel, the company is engaging in partnering discussions to strike a deal for phase III studies and beyond. – SynAct has a clear strategy, the right team and fresh funding to continue with its plan, says Anders Kronborg, Chairman of the Board. Read the full article at biostock.se (https://www.biostock.se/en/): https://www....

Following previous studies in rheumatoid arthritis, SynAct Pharma knows much more about the possibilies and requirements for assessing resomelagon's effect. The company is now acting on its strategy by initiating the filing process for a new clinical phase IIb study with resomelagon in patients with severe, newly diagnosed RA with signs of systemic inflammation. BioStock reached out to CEO Jeppe Øvlesen to learn more about the clinical trial, named ADVANCE. Read the full article at biostock.se (https://www.biostock.se/en/): https://www.biostock.se/en/2024/07/synact-pharma-moves-forward-...